Saama Closes $40 Million Financing with Perceptive Advisors to Drive Disruption in Clinical Analytics and Drug Development

March 25, 2019 Off By BusinessWire

CAMPBELL, Calif.–(BUSINESS WIRE)–Saama Technologies, Inc. (“Saama”), a leading clinical data analytics
platform firm, announced that it has closed a $40 million financing with
Perceptive Advisors. The new funding will be used to support the
expansion of Saama’s Life
Science Analytics Cloud (LSAC)
, an AI-powered platform disrupting
the planning, designing and conduct of clinical trials across various
stages of clinical development. LSAC seamlessly ingests, integrates,
curates, and harmonizes clinical trial operational and patient data from
proprietary and external data sources to deliver actionable,
regulatory-ready insights. LSAC’s novel deep learning approach
significantly compresses clinical program timelines from clinical plan
development to submission judgment for a New Drug Application (NDA).

“The pharmaceutical industry, patients, advocacy groups, and global
regulatory agencies are all eager for innovations that rapidly
accelerate clinical trials while driving down costs. We are excited to
lead that change with a differentiated data analytics platform. We
intend to use the proceeds of this financing to strengthen our ecosystem
of pharma and biotech partners, academia, data providers and CROs, and
build a suite of collective innovations leveraging our award-winning
LSAC platform
,” said Suresh Katta, Founder and CEO of Saama
Technologies. “Perceptive Advisors understands the dynamic clinical
development space and the need for adopting leading-edge technological
solutions for enabling our pharma and CRO partners to drive sustainable
and breakthrough clinical innovation.”

“Perceptive’s investment in Saama will enable this leading data
analytics company to continue to innovate at the highest level,” said
Sam Chawla, Portfolio Manager, Perceptive Advisors. “Partnering with
Saama at this exciting juncture in the company’s lifecycle opens up a
spectrum of future opportunities for Saama to positively impact clinical
operations and influence business outcomes for life sciences companies.”

The new financing brings the total Saama has raised since 2015 to $75
million. Torreya Partners served as financial advisor to Saama in
conjunction with this transaction.

About Saama Technologies, Inc.

Saama Technologies is the advanced clinical data and analytics company,
unleashing wisdom from data to deliver better business outcomes for the
life sciences industry. Saama’s unified, AI-driven clinical data
analytics platform seamlessly integrates, curates, and animates
unlimited sources of structured, unstructured, and real-world data to
deliver actionable insights across all therapeutic areas. The
award-winning platform gives unprecedented real-time visibility into
clinical data, enabling sponsors to file New Drug Applications (NDAs)
more efficiently to bring drugs to market faster and at lower costs. For
more information, visit http://www.saama.com.

About Perceptive Advisors

Founded in 1999, Perceptive Advisors focuses on supporting progress in
the life sciences industry by identifying opportunities and directing
financial resources toward the most promising technologies in modern
healthcare. The firm manages approximately $4 billion across its
strategies, including approximately $1 billion focused in its credit
opportunities vertical. The firm is headquartered in New York, NY. For
more information, visit http://www.perceptivelife.com.

Contacts

Crystal Black
Saama Technologies
[email protected]
408-371-1900